


The promises of TREG autoimmune therapy, *all in one hand*



Forward-looking statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements".

These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy.

By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

The promises of TREG autoimmune therapy, *all in one hand*




Largest, most advanced pipeline of cell therapies for autoimmune disease

Therapeutic area	Indication	Discovery	Preclinical	Phase I	Phase II	Phase III
Type 1 diabetes	Early onset (stage 3)	PTG-007+ / rituximab				
	Presymptomatic (stage 1/2)	PTG-007+ / rituximab				
Multiple sclerosis	Relapsing-remitting (RRMS)	PTG-007+ / routinely used MS drug				
	Primary progressive (PPMS)	PTG-007+ / routinely used MS drug				
Multiple sclerosis	RRMS/PPMS	CAR-TREGS				
Amyotrophic Lateral Sclerosis		CAR-TREGS				
Type 1 diabetes	Early onset (stage 1-3)	PTG-020				
	Early onset (stage 1)	TCR-TREGS				

**NEXT-GENERATION
ENGINEERED TREGS**

Based in Poland, with a *global* outlook

Shares (%)



- PAAN CAPITAL
- Venture Fundusz Inwestycyjny Zamknięty
- Marek-Trzonkowska Natalia
- Trzonkowski Piotr
- TFI Allianz
- PTE Allianz
- Myśliwiec Małgorzata
- Pozostali



PoITREG (Ticker PTG.WSE) – Market cap USD 67m

Free float 65%

PoITREG Share price / Volume 1yr



Share Statistics

- IPO in 2021 on Warsaw Stock Exchange
- **Market cap** PLN 273m (USD 67m)
- **Shares outstanding** 4,66m
- **Free Float** 65%
- **Held by insiders** 35,33%
- **Held by institutions** 38,22%
- **Current share price** PLN 58,60 (USD 14,13)
- **52-week high** PLN 65 (USD 15,7)
- **52-week low** PLN 31 (USD 7,5)

Experienced leaders, *front-line* scientists



Prof. Piotr Trzonkowski

CEO, Founder & Board Director

Professor of medical science, **creator of the TREG method**, world authority in the field of cells therapies



Mariusz Jabłoński

CBO, Board Director

20+ years of experience in management positions at pharma and healthcare companies such as Eli Lilly, Philips Healthcare



Paulina Kocenko-Merks

CFO, Board Director

15+ years of professional experience in financial management in large capital groups and public entities



Grzegorz Orlik

Head Medical Affairs

Medical doctor with over 20 years of experience in the pharmaceutical business, including over **15 years in international structures**. Experience, at Accord Healthcare, and at Sandoz, where he was medical manager.



Dan Shelly, PhD, MBA

Chief Business Development Officer

20 years of business development experience focused on advanced biologics, vaccines, recombinant proteins, cell and gene therapies. He has a proven track record of closing business development deals for a wide range of biotech companies.

Experienced leaders, *front-line* scientists



Camilo Ricordi,
MD, Professor of Medicine



Artur Tadeusz Bossowski,
MD, PhD, Professor of Medicine



Agata Przemysława Chrobot,
MD, PhD, Professor of Medicine



Kamil Chwojnicki
MD, PhD



Przemysława Jarosz-Chobot
MD, PhD, Professor of Medicine



Iwona Kurkowska-Jastrzębska
MD, PhD, Professor of Medicine



Wojciech Młynarski
MD, PhD, Professor of Medicine



Agnieszka Szadkowska
MD, PhD



Natalia Marek-Trzonkowska
Professor, MD, PhD



Małgorzata Myśliwiec
MD, PhD, Professor of Medicine



Robert Bonek
MD, PhD

Treg cells are a potential therapy for a range of auto-immune diseases





Fig 2. Lorem ipsum

PTG007 has shown the capacity to slow progression of T1D

A potential disease-modifying candidate therapy for early onset T1D


PTG007 has
a potential to reduce
insulin dependance...




....through a range of cellular mechanisms

- I Suppression of antigen presentation
- II Inhibition of activation of T helper (Th) and cytotoxic T effector (TC) via cell-to-cell interactions
- III Induction of apoptosis of monocytes/macrophages (Mono/Mac)
- IV Inhibition of B cell proliferation and induction of apoptosis
- V Induction of apoptosis of neutrophils
- VI Inhibition of function and proliferation of natural killer (NK) cells
- VII Inhibition of degranulation of mast cells

Using the immune system's own police force



TREGs **operate at the site** of inflammation only



TREGs **switch off** when the inflammation is over

TREGs keep the immune system in check and prevent other immune cells from attacking the body's own tissues.

Key milestones for value creation 2023-2025

Candidate	H1 24	H2 24	2025	Event
Regulatory approval facility Poland	●			Approvals to use new research and production facilities in Poland for further clinical studies
PTG-007+ (T1D early onset)	●			End of post-trial long-term safety/efficacy study (10-year follow up of patients)
PTG-007+ (T1D early onset)			●	Phase 2/3 clinical trial
PTG-007 (T1D presymptomatic)		●		Start Phase 2 clinical trial
PTG-007+ (MS, relapsing-remitting)		●		Start Phase 1/2a clinical trial
PTG-007 (MS, primary progressive)		●		Start Phase 1/2a clinical trial
CAR-TREGs (MS, ALS)			●	Start clinical trial
AgTREGs, TCR-TREGS (T1D)			●	Searching for Proof of Concept

TREG therapy is a growth market

Recent transactions:

Development of therapy for inflammatory bowel disease IBD

- 1,9 mld USD - biodollar




Development of TREG therapy

- 75 mln USD - upfront payment
- 45 mln USD - milestone



Development, production and commercialization of modified TREG cell therapies

- 85 mln USD - upfront payment
- 2 mld USD - milestone



\$1.9 billion

PTG-007 **potential peak sales** for newly diagnosed T1D (IQVIA estimate)

Key players



Type-1 Diabetes: combination therapy in PTG007+ trial shows *better remission*

December 2021 data




”

Any delay in the administration of insulin is significant, because it means that you have been successful in targeting the cause of the disease, and you need to take advantage of that.


IQVIA report

T1D: Superior results from combined therapy over any monotherapy

First loss of remission - censored



Total Daily Dose of Insulin per kg b.w.



Half of patients were in clinical remission at 24 months in Phase 2 study.

Full report: Zielinski et al. DOM 2022

What's next for *early onset* T1D?



Phase 2/3 study **ready to launch**, requires partner funding

Potentially pivotal study for market authorization

250 patients (5 x 50)

5 arms



Option to stop Phase 2 trial and start Phase 3 if one of the interventional arms shows **superior results**

Duration

18 months

Presymptomatic T1D: phase 2 study



Pediatric patients with
presymptomatic T1D

150 patients

4 arms



Protocol signed, contracting
of sites awaiting approval

Up to


5 years

Planned start

3Q2024

pending EMA approval

A therapeutic candidate for each stage of T1D



NEJM 1986; 314:1360

Can TREGS also be a game changer in MS?

>2.8 million

Multiple Sclerosis affects more than 2.8 million people worldwide

There are no curative therapies

TREGs have the potential to ameliorate MS as part of a combination therapy

\$33.98 billion

Market expected to reach \$33.98 bn by 2029, for a 3.75% CAGR

Promising early PoITREG results show remission

in case of intrathecal injection of TREG cells

MS: Promising *early signs* of efficacy

14 patients

Phase 1/2 RRMS study
with 14 patients


Almost no increase in volume
of existing lesions, almost no
new lesions in brain

3 years

Study dates
2015-2018

Intrathecal administration
showed positive efficacy
signal

Number of lesions



What's next? New phase 1/2 study in MS



One study each in primary
progressive MS (PPMS) and
relapsing-remitting MS (RRMS)

Each trial expected
to have three arms

3 arms



Expected start date: 2H 2024
for both trials

2024

A combined 105 patients:

60 for PPMS

45 for RRMS

Next generation


Engineered TREGS

”

We [...] view CART cell therapy [...] in refractory autoimmune disease as the most disruptive and high commercial potential opportunity since immune-oncology re-emerged in 2011

Andrew Baum, Citi research note, August 2023

CARTREGs as a platform for *neurodegenerative* disease



The CAR receptor directs TREG cells to glia cells, which **protect** the nervous system



This can **help the degradation** of neural cells in a range of autoimmune diseases



CARTREGs are a **platform** therapy for neurodegenerative disease

The first in-patient CARTREG trial in *neurodegenerative* disease?



Phase I clinical trial can start as soon as CMC approval, animal studies are finished

Two separate clinical trials planned:

MS

ASL



Partnership with AZ Therapies

PoITREG's long experience with TREGs will make it easier to obtain approval to start clinical studies

Expect trial launch late

2024/25

Security in one of Europe's largest development centres

PoITREG achieved nearly 100% purity in TREGS expanded ex vivo, and was **the first ever** to inject patients with autologous cells.

Building a state-of-the art *manufacturing* plant

2021



PolTREG started building one of the most advanced in Europe for cell and **gene therapy manufacturing** in 2021

2023



The new facility is now ready and expected to receive regulatory approval in 2023




Production facility for third parties for wide range of polyclonal and monoclonal therapies

Opportunities for own research



2100 sqm


It boasts 15 production lines, and 2,100 square metres of **laboratory space**



Building a state-of-the art *manufacturing* plant

Pharma companies

- Expand BD and Alliance Management Strategy
- Business partnerships



Clinical centres

- For early access therapies for patients with early-onset T1D

Pharma companies

- Up-and-running CDMO, GMP certified
- For full range of products: polyclonal, CARTreg, AgTreg



Academic partners

- For R&D

Contact us

office@poltreg.com

Botaniczna 20 Street,
Gdansk, Poland

Mariusz Jablonski , Chief Business
Officer
email

Chris Maggos, Cohesion Bureau,
Investor Relations
Email.....

poltreg.com

Innovative therapies
for autoimmune diseases

